Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that the Company will host a conference call and live audio webcast on Wednesday, March 16, 2016, at 8:30 a.m. ET to provide a 2015 transitional report and business update.
In April 2015, Tenax announced that its Board of Directors had approved a change in the Company’s fiscal year to a fiscal year beginning on January 1 and ending on December 31, such change beginning as of January 1, 2016. The Company’s next Annual Report on Form 10-K will be for the fiscal year ending December 31, 2016. The Company will file a Transition Report on Form 10-KT with the Securities and Exchange Commission (SEC) for the eight-month period ending December 31, 2015 on March 14, 2016.
To participate in the call, please dial 877-407-8029 (domestic) or 201?689?8029 (international) and refer to conference ID 13631862. A live webcast of the call can be accessed under “Events and Presentations” in the Investors section of the Company’s website at www.tenaxthera.com. An archived webcast recording will be available on the Tenax Therapeutics website beginning approximately two hours after the call.
About Tenax Therapeutics
Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market. The Company owns the North American rights to develop and commercialize levosimendan, and the United States Food and Drug Administration (FDA) has granted Fast Track status for levosimendan for the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome (LCOS). The Company is currently enrolling a Phase 3 trial with levosimendan in that indication, and is also supporting Imperial College London’s LeoPARDS trial for levosimendan in septic shock. For more information, visit www.tenaxthera.com.
Stern Investor Relations, Inc.
Jesse Baumgartner, 212-362-1200